If you have been reading about somatotroph and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
| Property | Value | Notes |
|---|---|---|
| Routine purity assay | Reversed-phase HPLC | Ultraviolet detection near 214 nm |
| Identity confirmation | Liquid chromatography–mass spectrometry | Mass shift reveals modification or truncation |
| Typical purity specification | Greater than 95 percent | Reported as main-peak area percentage |
| Long-term storage | Minus 20 degrees Celsius or colder | Sealed, protected from light |
| Principal degradation routes | Oxidation, deamidation, aggregation | Monitored individually during stability studies |
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
He will remain as an independent councillor for Tamworth. Martin Murray is appointed as temporary leader of Staffordshire County Council to replace him. 10 December – Chancellor Rachel Reeves tells the House of Commons that there were too many pre-budget leaks prior to her speech in November. Former swimmer Sharron Davies is named as one of three new Conservative peers; 25 new Labour peers and five Liberal Democrat peers are also announced. 11 December – Ben Bradley, a former Conservative MP and council leader, announces he is joining Reform UK. 12 December – The Treasury Committee launches a review of the Office for Budget Responsibility after it came under close scrutiny in the run up to the budget. Reform UK claims to have the largest party membership in the UK after a report in The Times that Labour's membership has fallen to below 250,000. Reform says it has 268,000 members, although political parties' figures are not externally verified. Reform wins its first election in Scotland after David McLennan is elected as a councillor in Whitburn and Blackburn in West Lothian, taking the seat from Scottish Labour. 14 December – Writing in The Sunday Telegraph, Conservative Party leader Kemi Badenoch says her party will scrap the impending UK ban on petrol and diesel vehicles if they win the next general election. 15 December – Former Democratic Unionist Party councillor William Ball is sentenced to fifteen months in custody for historical sexual offences committed against a young girl.
Some previous disputes, such as the Pedra Branca dispute, have been resolved by the International Court of Justice. Piracy in the Strait of Malacca has been a cause of concern for all three countries. Close economic ties exist with Brunei, and the two share a pegged currency value, through a Currency Interchangeability Agreement between the two countries which makes both Brunei dollar and Singapore dollar banknotes and coins legal tender in either country. The first diplomatic contact with China was made in the 1970s, with full diplomatic relations established in the 1990s. China has been Singapore's largest trading partner since 2013, after surpassing Malaysia. Singapore and the United States share a long-standing close relationship, in particular in defence, the economy, health, and education. Singapore has also increased co-operation with ASEAN members and China to strengthen regional security and fight terrorism, and participated in ASEAN's first joint maritime exercise with China in 2018. It has also given support to the US-led coalition to fight terrorism, with bilateral co-operation in counter-terrorism and counter-proliferation initiatives, and joint military exercises. As Singapore has diplomatic relations with both the United States and North Korea, and was one of the few countries that have relationships with both countries, in June 2018, it hosted a historic summit between US President Donald Trump and North Korean leader Kim Jong-un, the first-ever meeting between the sitting leaders of the two nations.
== Available forms == AzM is often used as active ingredient in organophosphate pesticides like Guthion, Gusathion (GUS), Gusathion-M, Crysthyron, Cotnion, Cotnion-methyl, Metriltrizotion, Carfene, Bay 9027, Bay 17147, and R-1852. This is why Guthion is often used as a nickname for AzM. Studies have shown that pure AzM is less toxic than GUS. This increased toxicity can be explained by the interactions between the different compounds in the mixture.
=== Cancer === Current clinical trials testing synthetic platelets offer a promising strategy for oncology applications by facilitating targeted drug delivery to tumors and reducing off-target toxicity in cancer therapy. Natural platelets were reported to interact with cancer cells through mechanisms such as immune evasion, angiogenesis, and metastasis. Specific to oncology, synthetic platelets are applied using targeted drug delivery. Platelet-mimicking nanoparticles developed from self-assembling peptides were found to adhere to tumor endothelial cells and induce localized coagulation, forming artificial clots that disrupt tumor vasculature. This approach reduces blood supply to the tumor, effectively starving cancer cells while preventing metastatic spread. Furthermore, synthetic platelets designed to deliver chemotherapy drugs can leverage natural platelet-tumor interactions to deliver drugs directly to cancerous cells, which has been seen to reduce off-target effects and improve therapeutic outcomes. Immunotherapy and radiation sensitization are additional application areas of platelet-mimicking particles. Platelet-inspired nanomedicine uses extracellular vesicles and platelet-derived biomaterials to enhance immune responses against tumors. These biomimetic platforms can be designed to carry immune checkpoint inhibitors and pro-inflammatory cytokines, which can help overcome immune evasion mechanisms employed by cancer cells.
Sources: en.wikipedia.org
November 20, 2007: Law concerning the control of immigration, integration, and asylum. December 17, 2007: Law containing various provisions adapting to Community law in economic and financial matters. January 21, 2008: Law ratifying Ordinance No. 2007-329 of March 12, 2007, concerning the Labor Code (legislative part). February 26, 2008: Law facilitating equal access for women and men to the mandate of general councilor. May 27, 2008: Law containing various provisions adapting to Community law in the field of combating discrimination. July 11, 2008: Letter from the President of the Republic to the Prime Minister concerning national orders. July 23, 2008: Law on the modernization of the institutions of the Fifth Republic; it notably provides for specifying in the first article of the French Constitution: "The law promotes equal access for women and men to electoral mandates and elective functions, as well as to professional and social responsibilities." August 4, 2008: Law on the modernization of the economy. September 2008: Report on the image of women in the media, by Michèle Reiser. January 16, 2009: Law ratifying Ordinance No. 2005-759 of July 4, 2005, reforming filiation and modifying or repealing various provisions relating to parentage. May 6, 2009: Decree on voluntary termination of pregnancy by medical means. 2010: The fight against violence against women becomes a national cause. February 8, 2010: Law to include incest committed against minors in the Penal Code and to improve the detection and care of victims of incestuous acts.
===== Venezuela ===== In May 2023, ahead of a South American summit to which all the presidents of the region were invited, Lula met with Venezuelan president Nicolás Maduro and stated that "you know the narrative that was built against Venezuela, of anti-democracy, of authoritarianism" and "it is in your hands, comrade, to build your narrative and turn this party around so that we can definitively win and Venezuela becomes a sovereign country again where only its people, through a free vote, say who will govern". Chilean president Gabriel Boric and Uruguayan president Luis Lacalle Pou, who were some of the summit attendees, disapproved of Lula's comments.
==== Opioid receptor modulators ==== Buprenorphine depot (Brixadi; Buvidal; CAM-2038; CAM-2048) – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor antagonist, and nociceptin receptor agonist – opioid-related disorders Buprenorphine extended-release (Atrigel buprenorphine; BUP-XR-Indivior; depot buprenorphine; RBP-6000; Sublocade; Subutex prolonged release) – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor antagonist, and nociceptin receptor agonist – opioid-related disorders Buprenorphine/naloxone sublingual (naloxone/buprenorphine; Sai Bo Song; SCH-000484; Suboxone) – combination of buprenorphine (non-selective opioid receptor modulator) and naloxone (orally/sublingually inactive opioid receptor antagonist) – opioid-related disorders Methadone (Zoryon) – μ-opioid receptor agonist – opioid-related disorders Nalmefene (Revex) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – opioid overdose, alcoholism Nalmefene (CPH-101; JF-1; Lu AA36143; nalmetrene; NIH-10365; ORF-11676; Selincro; Soberal) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – alcoholism Nalmefene nasal spray (intranasal nalmefene; Indivior; OPNT-003; Opvee) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – opioid-related disorders Nalorphine (Lethidrone, Nalline) – μ-opioid receptor antagonist, κ-opioid receptor agonist – opioid overdose Naloxone injection (Evzio; naloxone auto injector) – opioid receptor antagonist – opioid-related disorders Naloxone intranasal spray (Rezenopy) – μ-opioid receptor antagonist – opioid-related disorders Naloxone intranasal spray (Kloxxado; naloxone nasal spray) μ-opioid receptor antagonist – opioid-related disorders Naloxone multidose nasal spray (AP-003; Narcan) – μ-opioid receptor antagonist – opioid-related disorders Naloxone nasal spray (-12; LT-20; LT-21; LT-22; Naloxon B; Narcan Nasal Spray; OPNT-001) – μ-opioid receptor antagonist – opioid-related disorders Naltrexone controlled-release (Vivitrex; Vivitrol; XL-NTX; XR-NTX; ALKS-6428) – opioid receptor antagonist – alcoholism, opioid-related disorders Naltrexone oral (Nalorex; Nemexin; Revia) – opioid receptor antagonist – alcoholism, opioid-related disorders Other opioids (opioid agonist therapy) (e.g., dihydrocodeinone, extended-release morphine) – μ-opioid receptor agonists – opioid use disorder Tianeptine (Coaxil; Stablon; Tatinol) – μ-opioid receptor agonist, other actions – alcoholism
Sources: en.wikipedia.org
Chester Fisher died in 1965 at age 84. His sons maintained leadership of the company, with Aiken becoming Chairman and Benjamin becoming president. The youngest son, James Fisher, had the title Senior Vice President. Fisher Scientific Company issued its first public stock in 1965, and that year the company had $58 million in sales and close to a million customer transactions. In 1968 Fisher shares were listed on the New York Stock Exchange. In 1965 the company introduced the Differential Thermalyzer, a differential thermal analysis instrument. It acquired Pfeiffer Glass, Inc. in 1966, a manufacturer of high accuracy volumetric pipettes. The company released the Photometric Titralyzer that year, and a Hem-alyzer in 1968. In 1968, it purchased Massachusetts-based Jarrell-Ash Company, a producer of optical instrumentation, particularly for emission and atomic absorption spectroscopy. It acquired Chicago-based Stansi Scientific Company in 1967, expanding into educational science supplies. In 1976, Fisher Scientific established an Instrument Service Division. Fisher was acquired by Morristown, New Jersey–based Allied Corporation in 1981 for $330 million. At this time Benjamin R. Fisher was Chairman of the company, having gained the position in 1975 upon Aiken's retirement. Operating as a subsidiary of Allied Corporation (and later AlliedSignal Inc., and The Henley Group), Fisher established a Biotechnology Division in 1985. In 1991, The Henley Group sold a majority interest in Fisher through a public stock offering.
== Background == Albericio earned his Ph.D. in chemistry from the University of Barcelona in 1981. He became a full professor at the University of Barcelona in 1995 and later served as executive director of the Barcelona Science Park from 2005 to 2012, where he was involved in field of biotechnology entrepreneurship. From 2014 to 2015, he served as the founding rector of Yachay Tech University in Ecuador. Since 2016, he has been affiliated with the University of KwaZulu-Natal in South Africa as a research professor. Albericio’s research focuses on the development of methodologies for the synthesis of peptides and other bioactive compounds. He has contributed to the design and commercialization of numerous reagents and materials used in peptide synthesis, including ChemMatrix resin and OxymaPure. Albericio was honored with the Lifetime Achievement Award at the 2024 European Peptide Synthesis Conference (EPSC) in the Czech Republic, in recognition of his contributions to the field of peptide synthesis. He also serves a editor of the International Journal of Peptide Research and Therapeutics and as a Councillor for the American Peptide Society. Throughout his career, Albericio has published extensively, with over 900 scientific articles. He has a high number of citations to his work (49,559) and an h-index of 107.
== Pathophysiology == Atherogenesis is the developmental process of atheromatous plaques. It is characterized by arterial remodeling, leading to the subendothelial accumulation of fatty substances called plaques. The buildup of an atheromatous plaque is a slow process, developed over several years through a complex series of cellular events occurring within the arterial wall and in response to several local vascular circulating factors. One recent hypothesis suggests that, for unknown reasons, leukocytes, such as monocytes or basophils, begin to attack the endothelium of the artery lumen in cardiac muscle. The ensuing inflammation leads to the formation of atheromatous plaques in the arterial tunica intima, a region of the vessel wall located between the endothelium and the tunica media. Chronic inflammation within the arterial wall, driven by immune cells (e.g., macrophages), accelerates atherosclerotic plaque instability by promoting collagen breakdown and thinning the fibrous cap, increasing the likelihood of rupture and thrombosis. The bulk of these lesions is made of excess fat, collagen, and elastin. At first, as the plaques grow, only wall thickening occurs without narrowing. Stenosis is a late event, which may never happen and is often the result of repeated plaque rupture and healing responses, not just the atherosclerotic process. Autopsy studies have shown that the prevalence of coronary artery atherosclerosis in males from the United States, with an average age of 22.1 years, who died in war, ranges from 45% to 77.3%.
In 63 BCE, the Roman Republic conquered the kingdom. In 37 BCE, the Romans appointed Herod the Great as king of a vassal Judea. In 6 CE, Judea was fully incorporated into the Roman Empire as the province of Judaea. During this period, the main areas of Jewish settlement in the Land of Israel were Judea, Galilee and Perea, while the Samaritans had their demographic center in Samaria. Growing dissatisfaction with Roman rule and civil disturbances eventually led to the First Jewish–Roman War (66–73 CE), resulting in the destruction of Jerusalem and its Temple, which ended the Second Temple period. This event marked a cataclysmic moment in Jewish history, prompting a reconfiguration of Jewish identity and practice to ensure continuity. The cessation of Temple worship and disappearance of Temple-based sects facilitated the rise of Rabbinic Judaism, which stemmed from the Pharisaic school of Second Temple Judaism, emphasizing communal synagogue worship and Torah study, eventually becoming the predominant expression of Judaism. Concurrently, Christianity began to diverge from Judaism, evolving into a predominantly Gentile religion. Decades later, the Bar Kokhba revolt (132–135 CE) further diminished the Jewish presence in Judea, leading to a geographical shift of Jewish life to Galilee and Babylonia, with smaller communities scattered across the Mediterranean.
Sources: en.wikipedia.org
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the standard technique for purity and content. Mass spectrometry provides orthogonal confirmation of identity. The two are normally used together rather than in isolation.
Removing water slows hydrolysis and limits the mobility that drives aggregation. A dry powder is also less hospitable to microbial growth. These factors make cold storage of the solid form more forgiving than storage of a reconstituted solution.
Methionine oxidation, asparagine and glutamine deamidation, and non-covalent or covalent aggregation are the main routes reported for peptides of this class. Each is tracked as a separate impurity. Their relative abundance depends on formulation and storage history.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.